Reckitt Benckiser Group Plc

BASEL, Switzerland--(BUSINESS WIRE)-- TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Jeff Jonker and Mike Sherman to its Board of Directors. Both bring extensive careers in the strategic, financial and corporate development aspects of building leading biotechnology companies. Together, they will contribute to TOLREMO’s further growth and operational execution as the company advances its lead candidate, TT125-802, designed to prevent transcriptional cancer drug resistance, through a Phase 1 first-in-human clinical trial. "We welcome Jeff and Mike to our Board of Directors as we make steady progress with TT125-802 in the clinic and continue our evolution into a clinical-stage company with expanding operations,” said Stefanie Flückiger-Mangual, PhD, Co-founder and Chief Executive Officer of TOLREMO. “Jeff's extensive leadership experience and Mike's expertise in financial strategy within the life sciences sector are valuable assets as we continue our mission to overcome transcriptional drug resistance to a broad spectrum of targeted cancer treatments.” "Joining TOLREMO's board is an opportunity to contribute to a company making significant strides toward surmounting a universal problem for current and future targeted cancer therapies. I am eager to support TOLREMO in its clinical stage as it advances TT125-802 and help shape the company’s corporate strategy to ensure the team’s scientific knowledge is translated into tangible benefits for patients," said Jeff Jonkers, new board member at TOLREMO. “As a new member of the TOLREMO board, I look forward to applying my experience in guiding companies through critical growth phases to contribute to the company’s strategic financial perspective as we aim to maximize the potential of TT125-802,” said Mike Sherman, new board member at TOLREMO. Jeff Jonker is an accomplished biotechnology executive with a wealth of experience across various leadership roles in the industry. He has served as the President and CEO as well as a Director of Belharra Therapeutics since 2021, and he is currently a member of the Board of Directors of California Life Sciences. Prior to this, Jeff served as the CEO of Ambys Medicines, President of NGM Pharmaceuticals, and Senior Vice President, Corporate and Business Development at Theravance Biopharma. His other executive roles include CBO of Satori Pharmaceuticals, Vice President of Business Development and Corporate Strategy for Gloucester Pharmaceuticals prior to its acquisition by Celgene, as well as multiple leadership positions in the business development and legal groups at Genentech. Jeff began his career at Wilson Sonsini, representing clients in the life science and high-tech industries. Jeff holds a J.D. from Columbia University School of Law, an M.LITT. from the University of St. Andrews, and a B.A. from Claremont McKenna College. Mike Sherman is a seasoned executive with over 30 years of life science experience and an established track record in biotech leadership. He currently serves as Board Chair at Chimerix, Inc. and as a Board Director at Werewolf Therapeutics. Prior to this, Mike was the CEO of Chimerix, where he led the company's shift from antivirals to oncology, including the FDA approval and sale of TEMBEXA® and the progression of a Phase 3 glioma trial for its lead oncology drug. Before Chimerix, he was the CEO of Endocyte, transforming its market capitalization from $200 million to a $2.1 billion acquisition by Novartis in 2018. This transformation involved pipeline re-prioritization, the acquisition of PLUVICTO®, and the execution of a Phase 3 regulatory and clinical strategy. Mike’s tenure at Endocyte originally began in 2006 as CFO, where he contributed to its IPO and various financings. His earlier career included executive roles at Guidant Corporation, a cardiovascular device manufacturer later acquired by Boston Scientific Corporation. Mike’s previous board experiences include positions at BioSpecifics Technologies, Inc., Mead Johnson Nutrition, and service as the former Chairman of the Board of Trustees for the Children’s Museum of Indianapolis. Mike holds a B.A. in Economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth, where he graduated as a Tuck Scholar. About TOLREMO TOLREMO therapeutics' mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we discovered a pivotal mechanism that governs critical transcriptional resistance pathways. Our clinical compound TT125-802 is an orally available small molecule inhibitor designed to block these survival techniques to significantly improve the response rates and durability of established treatments. By stopping cancer drug resistance as it emerges, we aim to surmount a universal challenge for current and future targeted therapies for lasting patient benefit.

DUBLIN, March 12, 2024 /PRNewswire/ -- The "Global Personalized Retail Nutrition and Wellness Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering. Global Personalized Retail Nutrition and Wellness Market projects significant growth from USD 2.42 billion in 2023 to USD 3.67 billion by 2028. This notable market expansion is attributed to a Compound Annual Growth Rate (CAGR) of 8.67%. Market Overview & Dynamics This detailed industry analysis reveals key insights into market dynamics that include a wide array of macro and micro-economic factors impacting the sector. The report examines how emotional and rational decisions of stakeholders influence market trends and price signals beyond the conventional economic forces of supply and demand. Analytical Market Segmentations The market is dissected by Recommendation, with segments including Continuous, Fixed, and Repeat recommendations Applications Segments cover targeted demographics such as Children, Female, and Male consumers Geographically, the study covers in-depth data from key regions such as the Americas, Europe, Middle-East & Africa, and Asia-Pacific Company and Country Analysis This analysis offers a critical view of competitor strategies within the market, showcasing financial performance analyses of listed companies and recent developmental strategies. Furthermore, the study encompasses detailed insights into specific countries, investigating the market from a granular perspective. Strategic Tools: Competitive Quadrant & Ansoff Analysis The report features innovative tools like the Competitive Quadrant and Ansoff Analysis to strategically analyze market players and provide a roadmap for industry growth. Factors such as new product launches, growth strategies, and market share expansion play a central role in this extensive analysis. Impact of Covid-19 Underpinning this study is an evaluative look at the effects of the Covid-19 pandemic on the Global Personalized Retail Nutrition and Wellness Market. The pandemic's repercussions have prompted market adjustments and strategic shifts within the industry. Regulatory Landscape Key regulatory frameworks across various regions and their implications on the sector are thoroughly discussed, ensuring readers are well-informed on the compliance requirements affecting market operations. Competitive Analysis The report encompasses an exhaustive competitive analysis, providing proprietary tools to benchmark companies' performance and industry placement. Comprehensive Market Insights Potential market entrants and existing players will discover a wealth of information, including historical data, current market trends, and forward-looking projections. The report's in-depth analysis offers a foundational understanding of the parent industry and vital market dynamics. Investors, stakeholders, and industry specialists are poised to gain a strategic edge from this report, which serves as a testament to the burgeoning Personalized Retail Nutrition and Wellness sector and its diverse market segments. Market Dynamics Drivers Growing Consumer Awareness of Health and Wellness Rising Geriatric Population and Prevalence of Several Disorders Restraints High Cost of Equipment and Difficulty in Maintaining Patient Database Opportunities Development in Metabolic Profiling Technologies Rising Adoption of Devices to Track Health Data Growing Trend of Customized Diet Plans Challenges Lack of Research Activities concerning Nutrigenomics Companies Mentioned Bactolac Pharmaceutical, Inc. Balchem Inc. Bayer Ag Baze Labs GmbH Care/of. (Noho Health Inc.) Cargill, Inc. DNAfit Life Sciences Ltd. DuPont de Nemours, Inc. General Mills, Inc. GSK PLC Habit Food Personalized, LLC Habit LLC Herbalife Nutrition Ltd. Mead Johnson & Company, LLC Metagenics, Inc. Nature's Bounty, Inc. Noom, Inc. Nutritional genomics Pfizer, Inc. Vitamin Packs, Inc. Wellness Coaches USA, LLC For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Lab testing found numerous acne products formulated with benzoyl peroxide, including face washes, creams, and spot treatments, degrade to cancer-causing benzene under normal use and handling. LOS ANGELES, March 8, 2024 /PRNewswire/ -- Wisner Baum filed multiple class actions alleging several companies sold benzoyl peroxide (BPO) acne products without warning consumers that they contain unsafe levels of benzene, a potent human carcinogen. Class action attorneys Stephanie B. Sherman and R. Brent Wisner filed the complaints (Example Case: Howard et al. v. Alchemee, LLC and Taro Pharmaceutical USA, Inc., Case No. 2:24-cv-01834) on behalf of consumers who allege the following companies fraudulently marketed and sold acne face washes, creams, and other products when they knew or should have known that the products degrade to benzene: Alchemee, LLC and Taro Pharmaceutical USA, Inc. (Proactiv BPO products) CVS Pharmacy Inc. and CVS Health Corp. (CVS Health Acne Treatment Cream and CVS Health Acne Control Cleanser) RB Health, LLC (Clearasil Rapid Rescue Spot Treatment Cream and Clearasil Stubborn Acne Control 5 in 1 Spot Treatment Cream) Target Corp. (Up & Up BPO products) Genomma Lab USA, Inc. (Asepxia Acne Spot Treatment Cream) Walgreens Boots Alliance, Inc. (Daily Creamy Benzoyl Peroxide Acne Face Wash and Maximum Strength Acne Foaming Wash) The class actions follow independent testing from Valisure, an independent accredited laboratory that uses validated analytical methods to test drugs and consumer products for safety. Valisure tested 99 BPO-formulated products and found that some yielded benzene at levels 800 times 2 ppm, the maximum amount allowed in any U.S. regulated drug. Some of the benzene levels were many times higher than 2 ppm, reaching as high as 1700 ppm for Proactiv's 2.5% BPO Cream and 1600 ppm for Target's Up & Up 2.5% BPO Cream. Valisure included its testing results in a Citizen's Petition to the FDA and demanded an immediate recall of all BPO products to protect public health. According to the lawsuit allegations, the defendant companies continued to advertise and sell BPO products, ignoring the FDA safety alert on the dangers of benzene in consumer products and a directive to test products for benzene. The degradation of benzoyl peroxide to benzene was first reported in scientific literature in 1936, attorneys say, so the companies knew or should have known their products would degrade and form benzene. "These companies say their face washes and creams are safe, but they have no basis to make this claim because they aren't actually testing their products for basic safety," says attorney Stephanie Sherman. "Our clients never would have purchased these products had they known they were exposing themselves to a dangerous carcinogen." About Wisner Baum Los Angeles-based Wisner Baum has successfully litigated cases against many of the world's largest pharmaceutical companies. Since 1985, the firm has earned a reputation for breaking new legal ground, holding corporations accountable, influencing public policy, and raising public awareness on important safety issues. Across all practice areas, the firm has won over $4 billion in settlements and verdicts. Media Contact: Robin McCall Director of Public Relations Wisner Baum [email protected] SOURCE Wisner Baum